The expression of somatostatin receptor subtypes in immunohistochemistry and the response to somatostatin analogue therapy in non-functioning pituitary adenomas

Zawada, Natalia Bozena; Kunert‐Radek, Jolanta

doi:10.1530/endoabs.63.p1059

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gonzales et al showed high expression of SSTR3 followed by SSTR2, -5 and -1 by qPCR and further emphasized increased expression of SSTR3, -2 and -5 at protein level by immunohistochemistry in NFPA [ 326 ]. Meanwhile, Zawada and Kunert-radek reported the presence of all SSTR subtypes with a common expression of SSTR5, -2 and -1 with strong expression of SSTR1 and SSTR3 [ 327 ]. Taboada et al also showed high mRNA expression for SSTR3 in NFPA cases [ 328 ].…”

Section: Somatostatin Receptors and Pituitary Tumourmentioning

confidence: 99%

Somatostatin and Somatostatin Receptors in Tumour Biology

Kumar

2023

IJMS

View full text Add to dashboard Cite

Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release from secretory or immune cells, the first most appreciated role that SST exhibits is the antiproliferative effect in target tissue that served as a potential therapeutic intervention in various tumours of different origins. The SST-mediated in vivo and/or in vitro antiproliferative effect in the tumour is considered direct via activation of five different somatostatin receptor subtypes (SSTR1-5), which are well expressed in most tumours and often more than one receptor in a single cell. Second, the indirect effect is associated with the regulation of growth factors. SSTR subtypes are crucial in tumour diagnosis and prognosis. In this review, with the recent development of new SST analogues and receptor-specific agonists with emerging functional consequences of signaling pathways are promising therapeutic avenues in tumours of different origins that are discussed.

show abstract

Section: Somatostatin Receptors and Pituitary Tumourmentioning

confidence: 99%

Somatostatin and Somatostatin Receptors in Tumour Biology

Kumar

2023

IJMS

View full text Add to dashboard Cite

show abstract

The expression of somatostatin receptor subtypes in immunohistochemistry and the response to somatostatin analogue therapy in non-functioning pituitary adenomas

Cited by 1 publication

References 0 publications

Somatostatin and Somatostatin Receptors in Tumour Biology

Somatostatin and Somatostatin Receptors in Tumour Biology

Contact Info

Product

Resources

About